User:Mr. Ibrahem/Oritavancin

Oritavancin, sold under the brand name Orbactiv among others, is an antibiotic used to treat skin and skin structure infections such as cellulitis and skin abscesses. It is also effective against MRSA. It is given by injection into a vein.

Common side effects include diarrhea, nausea, dizziness, headache, itchiness, fever, and liver problems. Safety in pregnancy is unclear. It is a glycopeptide specifically a lipoglycopeptide and is similar to vancomycin. It works by stopping bacteria from making their cell wall.

Oritavancin was approved for medical use in the United States in 2014 and Europe in 2015. In the United States a course of treatments costs about 3,000 USD. It; however, is not commercially available in the United Kingdom or Europe as of 2021.